At the presentation of the BioCryst Pharmaceuticals, Inc. financial results for the third quarter of 2015 Jon P. Stonehouse, President & CEO, said:
“The completion of enrollment of our OPuS-2 trial of avoralstat and the successful outcome of the Phase 1 healthy volunteer study of BCX7353 have positioned both programs to reach important value creating events in 2016. We expect to initiate the APeX-1 (Angioedema ProphylaXis) proof of concept trial of BCX7353 in HAE patients and to report OPuS-2 results by early 2016. These oral kallikrein inhibitors have the potential to revolutionize HAE treatment, providing patients the ability to lead normal lives.”
(Source: BioCryst)
